Stephens & Co. Maintains Overweight on West Pharmaceutical Servs, Lowers Price Target to $390
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jacob Johnson has maintained an Overweight rating on West Pharmaceutical Servs (NYSE:WST) but lowered the price target from $420 to $390.

October 27, 2023 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
West Pharmaceutical Servs' price target has been lowered from $420 to $390 by Stephens & Co., though the Overweight rating is maintained.
The lowering of the price target by Stephens & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Overweight rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100